Lea Eslava-Kim, PharmD

Most Recent Articles by Lea Eslava-Kim, PharmD

Doravirine Demonstrates Non-Inferiority in Phase 3 HIV Study

By Feb 15, 2017

Merck announced positive results from the pivotal Phase 3 study of doravirine (MK-1439), evaluating its efficacy and safety for the treatment of HIV-1 infection.vvvv

FDA Fast Tracks Novel Combo Drug for Treatment Resistant Depression

By Feb 14, 2017

The FDA has granted Fast Track designation to the investigational drug AXS-05 (Axsome Therapeutics) for patients with treatment resistant depression (TRD).

Two-Drug HIV Combo as Effective as Three-, Four-Drug Regimen in Phase 3 Studies

By Feb 14, 2017

Janssen announced positive data from the SWORD Clinical Trial Program of the two-drug regimen dolutegravir (ViiV Healthcare) and rilpivirine (Janssen) for the maintenance treatment of HIV-1 infection in patients who have already achieved viral suppression.

Inhaled Levodopa Shows Promise for OFF Periods in PD Patients

By Feb 09, 2017

Acorda Therapeutics announced statistically significant results from the Phase 3 study of CVT-301, an investigational inhaled formulation of levodopa, for the treatment of OFF periods in patients with Parkinson's disease (PD) on an oral carbidopa/levodopa regimen.

FDA Accepts Zilretta NDA for Osteoarthritis Knee Pain

By Feb 07, 2017

The FDA has accepted for review the New Drug Application (NDA) for Zilretta (FX006; Flexion Therapeutics) for the treatment of patients with osteoarthritis (OA) of the knee.

More Articles by Lea Eslava-Kim, PharmD